Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer

NCT05030246 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Refractory Metastatic Digestive System Carcinoma
Primary Peritoneal Cancer

Interventions

DRUG: Surufatinib/Toripalimab

Sponsor

Peking University